83 results Hello new school year, hello new insolvency legislation: amendments to insolvency law enter into force today Today the Act of 7 June 2023 transposing the EU Restructuring Directive (2019/1023) enters into force. Digital Markets Act: “with great power must come great responsibility” The countdown is on for digital giants. The entry into force of the Digital Markets Act (DMA) on 1 November 2022 triggered a to do list for potential gatekeepers with 2 May 2023 as the next key date to keep in mind: see our DMA infographic. The Foreign Subsidies Regulation – beware and get your data ready! Earlier this year, the Foreign Subsidies Regulation (FSR) entered into force to close a loophole in EU regulations aimed at creating a level playing field within the internal market. Belgian Competition Authority confirms jurisdiction for M&A transactions in hospital sector On 14 July 2023, the Belgian Competition Authority confirmed its jurisdiction to review M&A transactions between hospitals, regardless of whether these hospitals belong to the same hospital network. CJEU confirms “right of explanation” in battle between trade secrets and algorithmic transparency The CJEU's recent ruling emphasizes the GDPR's demand for algorithmic transparency in automated decisions, challenging companies to explain their logic. The decision also shows the difficulty of balancing such transparency with trade secret protection. Amsterdam District Court rules in Schiphol A-Pier termination case Amsterdam District Court ruled that Schiphol's termination of the A-Pier construction contract was unlawful. Stibbe successfully represented the consortium BN-TAV in the proceedings concerning design responsibility and termination criteria. No reduction order for Shell on appeal: what does this mean? Shell climate case on appeal: no CO2 reduction order. What does this mean for the future? And for other companies? PFAS: the latest developments on its legal status and regulation Last summer, PFAS was frequently in the news, including a study by RIVM on PFAS in the blood of the Dutch population. This blog discusses the developments concerning the legal status and regulation of PFAS. Including scope 3 emissions in environmental impact assessments used in public decision-making In this blog post, we discuss the role that Scope 3 emissions can play in project permitting and environmental impact assessments. We do this in the light of a landmark decision by the UK Supreme Court on 20 June 2024. C'est le ton qui fait la musique – The end of employer copyrights? The CJEU decision in the National Orchestra of Belgium decision shakes up employer copyright in the Netherlands. With new consent and compensation requirements, are your employment contracts still airtight? Discover the implications of the decision here. If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. Pagination Previous page Page 2 Page 3 Page 4 Current page 5
Hello new school year, hello new insolvency legislation: amendments to insolvency law enter into force today Today the Act of 7 June 2023 transposing the EU Restructuring Directive (2019/1023) enters into force.
Digital Markets Act: “with great power must come great responsibility” The countdown is on for digital giants. The entry into force of the Digital Markets Act (DMA) on 1 November 2022 triggered a to do list for potential gatekeepers with 2 May 2023 as the next key date to keep in mind: see our DMA infographic.
The Foreign Subsidies Regulation – beware and get your data ready! Earlier this year, the Foreign Subsidies Regulation (FSR) entered into force to close a loophole in EU regulations aimed at creating a level playing field within the internal market.
Belgian Competition Authority confirms jurisdiction for M&A transactions in hospital sector On 14 July 2023, the Belgian Competition Authority confirmed its jurisdiction to review M&A transactions between hospitals, regardless of whether these hospitals belong to the same hospital network.
CJEU confirms “right of explanation” in battle between trade secrets and algorithmic transparency The CJEU's recent ruling emphasizes the GDPR's demand for algorithmic transparency in automated decisions, challenging companies to explain their logic. The decision also shows the difficulty of balancing such transparency with trade secret protection.
Amsterdam District Court rules in Schiphol A-Pier termination case Amsterdam District Court ruled that Schiphol's termination of the A-Pier construction contract was unlawful. Stibbe successfully represented the consortium BN-TAV in the proceedings concerning design responsibility and termination criteria.
No reduction order for Shell on appeal: what does this mean? Shell climate case on appeal: no CO2 reduction order. What does this mean for the future? And for other companies?
PFAS: the latest developments on its legal status and regulation Last summer, PFAS was frequently in the news, including a study by RIVM on PFAS in the blood of the Dutch population. This blog discusses the developments concerning the legal status and regulation of PFAS.
Including scope 3 emissions in environmental impact assessments used in public decision-making In this blog post, we discuss the role that Scope 3 emissions can play in project permitting and environmental impact assessments. We do this in the light of a landmark decision by the UK Supreme Court on 20 June 2024.
C'est le ton qui fait la musique – The end of employer copyrights? The CJEU decision in the National Orchestra of Belgium decision shakes up employer copyright in the Netherlands. With new consent and compensation requirements, are your employment contracts still airtight? Discover the implications of the decision here.
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.